Retinoic acid
By selecting your device, the default minimum transfer time will be set.
Please Log In to transfer IC
Log In
Add to Complex
Primary Application
Imprint
For what
Integumentary
Blood and Cardiovascular
Immune and Lymphatic
Mitochondrial and Energy Production
Source
Allopathy
For whom
People
All Trans Retinoic Acid (ATRA) is FDA approved in the treatment of promyelocytic leukemia. ATRA is a strong differentiating agent. As such, ATRA has potential as a therapy in a number of cancers, especially in the context of IC medicines. ATRA binds to retinoic acid receptors, and subsequently activates DNA transcription activity to move immature (e.g. malignant) cells toward normal maturation. Consider the use of ATRA in cases of cancer and precancerous lesions, including polyps, actinic keratosis, and others.
Please select language
Select